Rituximab monotherapy, rather than rituximab plus antiviral drugs, for initial treatment of severe hepatitis C virus-associated mixed cryoglobulinemia syndrome: comment on the article by Terrier et al.
Salvatore
S
De Vita
Luca
L
Quartuccio
D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000998:Antiviral Agents / Q000008:administration & dosage*; D003449:Cryoglobulinemia / Q000150:complications*; D004359:Drug Therapy, Combination; D006526:Hepatitis C / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D000069283:Rituximab; D013577:Syndrome
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000998:Antiviral Agents; D000069283:Rituximab